Envato
Total Consideration
$250.2M
Purchase-Price Allocation
Goodwill
$169.2M
Intangibles
$31.0M
Liabilities Assumed
$166.1M
Deferred Tax Liability
—
3 years of history · ending 2025-12-31 · SEC EDGAR
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | 1.50% | 1.60% | 1.60% | 2.20% | 2.90% | 2.50% |
| Foreign Rate Differential | 0.50% | 0.50% | 0.80% | 0.40% | 11.50% | — |
| Other Adjustments | — | — | — | — | — | — |
| R&D Tax Credits | — | — | — | 4.00% | 9.40% | 0.40% |
| FDII Deduction | — | 5.50% | 8.20% | 6.40% | 8.50% | 0.50% |
| SBC (Nondeductible) | 2.40% | -0.60% | 1.40% | 2.60% | 6.70% | 4.10% |
| Valuation Allowance Change | 0.90% | 0.80% | 1.20% | 1.30% | 2.10% | — |
| Tax Law Change | — | — | — | — | — | — |
| Qualified Production Activities (Legacy DPAD) | — | — | — | — | — | — |
| Effective Tax Rate | 19.80% | 12.30% | 16.40% | 10.00% | 42.60% | 39.60% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | $17.8M | $12.9M | $14.9M | $12.2M | $26.6M | $29.8M |
| Income Taxes Paid (Cash) | $8.8M | $19.1M | $23.4M | $33.1M | $34.0M | $20.2M |
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Total Consideration
$250.2M
Purchase-Price Allocation
Goodwill
$169.2M
Intangibles
$31.0M
Liabilities Assumed
$166.1M
Deferred Tax Liability
—
Purchase-Price Allocation
Goodwill
$189.0M
Intangibles
$31.3M
Liabilities Assumed
$168.5M
Deferred Tax Liability
$271.0K
Purchase-Price Allocation
Goodwill
$19.8M
Intangibles
$300.0K
Liabilities Assumed
$2.4M
Deferred Tax Liability
$271.0K
Total Consideration
$6.0M
Purchase-Price Allocation
Intangibles
$21.0M
Assets Acquired
$50.3M
Liabilities Assumed
$6.0M
Share price: $28.85
Per-case litigation disclosures sourced from us-gaap:LossContingenciesByNatureOfContingencyAxis dimensional XBRL. Coverage is sparse — most filers aggregate at the parent level (JNJ talc, PFE opioid) — but high-value when per-case disclosure exists. Loss estimate is either a single point or a low/high range, depending on how the issuer values the contingency.
As of 2025-12-31
| Case | Estimated Loss | Damages Sought | Settlement |
|---|---|---|---|
| Indemnification Guarantee | — | — | — |
Phase 1: currency selection stored in the URL. Conversion ships in Phase 2 (see ADR-0003).